COMING SOON: The Illumina NovaSeq X is a next-gen sequencer offerering unprecedented throughput, generating billions of reads at an affordable cost. It can produce up to 8 TB of data from a single run ...

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

The Illumina NextSeq 1000 is an NGS sequencing system designed to miniaturize sample and reagent volumes and increase read output. The NextSeq 1000 is capable of many sequencing applications, ...

Illumina (NASDAQ: ILMN) a global leader in genomics, and LGC Biosearch Technologies™, a pioneer in agricultural genomics, ...

By combining Biosearch Technologies' targeted genotyping-by-sequencing library preparation methodology (Amp-Seq) with Illumina's proven and highly scalable sequencing technology, the partnership ...

GRAIL faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Click here to ...

As the Distinguished William S. C. Chang Endowed Chair in the UC San Diego Jacobs School of Engineering’s Department of ...

ANGLE ANNOUNCES NEXT GENERATION SEQUENCING ASSAY AGREEMENT WITH NUPROBE. Option for exclusive licence to highly sensitive NGS assay for use with CTCs and dual analysis of CTCs wit ...

In a case that had been closely watched across multiple industries, Illumina chose to divest Grail in the light of legal action from the European Commission and the US Federal Trade Commission.

The NGS panel, which has been validated on the Illumina sequencer, enables highly sensitive and specific detection of over 6,500 DNA mutations in 61 clinically relevant genes and been found to be ...